( nd other pain related conditions. POZEN...)Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free,Response Across Multiple Attacks,Health

nd other pain related conditions. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has a development and a commercialization alliance with GlaxoSmithKline. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN".

For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

    POZEN Inc. sponsored and GlaxoSmithKline supported these studies.


    Contacts:

    GSK US Media                  Robin Gaitens, 919-483-2839

    GSK US Analyst/Investor       Frank Murdolo, 215-751-7002

                                  Tom Curry, 215-751-5419


    POZEN Inc. Investor           Bill Hodges, Chief Financial Officer,

                                  919-913-1030

                                  Fran Barsky, Director, Investor Relations,

                                  919-913-1044

    POZEN Inc. Media              Andrea Johnston, Pure Communications,

                                  910-681-1088

CONTACT: Robin Gaitens, +1-919-483-2839, or Analyst/Investor, FrankMurdolo, +1-215-751-7002, or Tom Curry, +1-215-751-5419, all ofGlaxoSmithKline; or Bill Hodges, Chief Financial Officer, +1-919-913-1030,or Fran Barsky, Director, Investor Relations, +1-919-913-1044 both of POZENInc., or Media, Andrea Johnston of Pure Communications, +1-910-681-1088,for POZEN Inc.

Ticker Symbol: (:POZN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

'"/>




Page: 1 2 3 4
Related medicine technology :

1. Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
3. Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA
4. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
5. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
6. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
7. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
8. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
9. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
10. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine